PRINCETON, N.J., June 10, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc., (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, today announced that its request for an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) has been granted. The Company will host a conference call today at 10:00 a.m. ET to discuss a business update, including recent milestones and key near-term goals. The call-in number is 844-835-7433.